Survey Finds Teens and Young Adults Treat Acne Reactively

Galderma Laboratories, LP’s new national survey revealed that more than 1,000 teens and young adults who have experienced acne struggle emotionally with their breakouts, yet treat it reactively and are anxious for results and effective acne treatments without ever visiting a dermatologist or primary care physician (PCP).

“Acne can widely impact teens and young adults, especially on an emotional level, yet many only treat their acne reactively and expect immediate results,” said Dr. Dendy Engelman, NYC-based board-certified dermatologist and Galderma consultant. “Acne sufferers have options, including prescription treatment options for patients with acne ranging from mild to moderate to severe inflammatory acne.”

Patients need to be educated about the need to see a physician, especially if their acne hasn’t improved within two weeks after using an OTC treatment. And, when treating teens and young adults, it’s important to understand how they feel about their acne and what they expect from treatment in order to best manage expectations and create the best treatment plan.

The Galderma survey, an online survey among 1,000+ teens and young adults 13-22 years of age who have had acne and tried at least one OTC acne treatment developed by Galderma with Kelton, using an email invitation, revealed:

  • Teens and young adults struggle emotionally and steer clear of cameras, mirrors, and social media: While experiencing acne, 69 percent of teens and young adults have taken less pictures of themselves; many also avoid mirrors (40 percent), spend more time in their rooms (36 percent) and stay off social media (25 percent). Specifically those with more severe acne have stayed off social media (46 percent) compared to mild and moderate sufferers (23 percent).
  • Among teens and young adults, females tend to be more embarrassed about the acne they experience and are concerned about its implications: When experiencing acne, more girls than boys (74 vs. 58 percent) have avoided looking in the mirror.
  • Despite this, 56 percent of teens and young adults only treat their acne with OTC products reactively and are impatient for OTC products to work right away: On average, results after using an OTC treatment are expected within three days; and 28 percent who are unsatisfied with results move on to another OTC option after a few weeks. Approximately half have jumped to using a new OTC acne product before finishing an old one and have even administered multiple OTC treatments on their skin at the same time. For those experiencing more severe acne than usual, almost a third (31 percent) would be most likely to try an OTC treatment—fewer would prioritize a visit to a physician for a prescription (18 percent) or advice (16 percent).
  • Most teens and young adults are concerned about being able to find effective OTC treatment options: In fact, almost all (94 percent) would make sacrifices if it meant they’d never have acne again, including giving up Snapchat (57 percent) or Instagram (51 percent) for six months, wearing the same clothes as their friends (44 percent) and giving up dessert for a year (41 percent).
  • Physicians, including dermatologists and PCPs, are rarely consulted for acne-related issues: More than 75 percent of teens and young adults report that they visit dermatologists less than once a year, if ever. In fact, 44 percent of teens and young adults don’t know a PCP is able to provide them with a prescription for acne treatment.

BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01

BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01.

Watch it Now

IOL Exchange for a Trifocal Lens Implant

TARGETING PIH IN ACNE-PRONE SKIN

Management of PIH, a common sequela of acne, is a challenge. Some interventions patients try can worsen the condition and damage the skin. A combination approach including salicylic acid, a retinoid, and procedures like chemical peels can be effective, says Dr. Desai, but timing is critical.

The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include reduction of Propionibacterium acnes (P. acnes) and cutaneous tolerance of the BPX-01 formulation.

Nonclinical studies show the BPX-01 topical gel formulation of minocycline can penetrate the epidermis to deliver the antibiotic to the dermis layer of skin where the condition develops. BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline, the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne vulgaris. It is anticipated that BPX-01 may effectively treat acne with lower, and therefore potentially safer, dosages of the antibiotic.

The FDA has previously found oral minocycline to be safe. However, the high dosage required to make the oral version effective against acne often causes undesirable side effects. BPX-01 is anticipated to be a break-through alternative to the oral products currently available. Phase 2a is expected to end by mid-year.

Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam for Papulopustular Rosacea

Foamix Pharmaceuticals Ltd. completed enrollment in a Phase 2 clinical trial of FMX103 for the treatment of papulopustular rosacea.

“We are pleased to have reached full enrollment of our Phase 2 study earlier than we originally anticipated,” said Dov Tamarkin, PhD, Chief Executive Officer of Foamix Pharmaceuticals. “There is a significant unmet need for safe and effective alternatives for the treatment of rosacea. We believe FMX103 has the potential to offer meaningful benefits over the current standard of care, and we look forward to receiving the results of this study later this year.”

In this Phase 2 double-blind, randomized, placebo-controlled trial, 233 patients have been enrolled in 18 sites throughout Germany. Patients were randomized to receive FMX103 (3% minocycline foam), FMX103 (1.5% minocycline foam) or vehicle foam over 12 weeks, followed up by a 4-week post-treatment evaluation. The primary endpoints are safety, tolerability and efficacy in the treatment of moderate-to-severe papulopustular rosacea. Foamix expects to develop FMX103 in the US, under the FDA’s 505(b)(2) regulatory pathway.

Foamix expects to report top-line results from this Phase 2 study by the end of the year. n